Hepion pharmaceuticals' phase 2 ‘altitude-nash' trial achieves primary and secondary endpoints, including improvement in liver function and multiple nash biomarkers

- improvements in physiologic liver function and key nash biomarkers including alt, proc3, piiinp and elf - - results reinforce rencofilstat's direct antifibrotic mode of action; increases confidence for reductions in fibrosis in ongoing phase 2b ‘ascend-nash' paired biopsy trial - edison, n.j., may 22, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced positive topline results from its recently completed phase 2 altitude-nash clinical trial.
HEPA Ratings Summary
HEPA Quant Ranking